Right now, a company can put a brand-new ingredient into the U.S. food supply and FDA may never see its name until the product is already on shelf.

That’s not a loophole in the sense of someone breaking a rule. It’s how the Generally Recognized as Safe framework has worked since FDA replaced its old GRAS affirmation petition process with a voluntary notification program in 1997, later finalized in 2016.[1] A company can hire its own panel of qualified experts, reach an independent conclusion that an ingredient is safe for its intended use based on generally available science, and start selling. Telling FDA about that conclusion is optional. Most companies do file a voluntary notice, because FDA’s “no questions” letter is useful for retailers, co-packers, and liability lawyers. But nothing requires it. That path is usually called “self-affirmed GRAS,” and it has been the quiet legal foundation under a lot of the novel ingredients showing up in functional foods, protein products, and better-for-you formulations over the last decade.

HHS proposed changing that on August 10, 2026, and FDA published the actual rule text in the Federal Register the next day as “Substances Generally Recognized as Safe,” 91 FR 51834, under docket FDA-2025-N-3262.[2] The proposal would amend 21 CFR Parts 170 and 570 to require GRAS notices for covered uses of substances in human and animal food, including both ingredients added directly and substances that migrate into food indirectly, such as through packaging. There are seven specified exceptions, mostly covering substances FDA has already reviewed in some other way.[3]

Here is the distinction that matters most, and the one worth getting right: this isn’t the same as turning GRAS substances into food additives that require FDA premarket approval. Food additive status under the FD&C Act is a much heavier legal category, requiring FDA sign-off before a substance can be used at all. The proposed rule stops well short of that. FDA’s own text says the mandatory notification requirement “would not, unlike with food additives, constitute a premarket review and approval requirement.” Companies could still introduce a substance before FDA ever files, or even reviews, a notice. Non-compliance would feed into how FDA prioritizes post-market scrutiny rather than blocking a launch outright.[3] So this is a documentation and visibility rule before it’s anything else. FDA wants a paper trail. It’s not asking permission to exist yet.

For ingredients already on the market under a prior self-GRAS conclusion, the proposal includes a one-year, time-limited streamlined submission window once a final rule takes effect. Companies could file a lighter notice that skips the full supporting data package, though they would still need to disclose any prior FDA correspondence, including “cease to evaluate” letters. The streamlined path wouldn’t be available if FDA had previously told a company its GRAS basis was insufficient or that a substance wasn’t GRAS at all.[3]

HHS Secretary Robert F. Kennedy Jr. framed the change in blunt terms, saying ingredient manufacturers and sponsors “have exploited a loophole that has allowed new ingredients and chemicals, often with unknown safety data, to be introduced into the U.S. food supply without notification to the FDA or the public.”[4] Whatever you think of the administration attached to it, the underlying point isn’t really disputed in the regulatory world: FDA genuinely doesn’t know the full universe of substances being sold under self-affirmed GRAS conclusions, because nobody has ever been required to tell it.

FDA estimates the rule would cost industry roughly $89.6 million in present value over ten years, a relatively small number for a change this structural, which suggests the agency expects most of the burden to land on paperwork rather than reformulation.[5] Public comments are open through December 9, 2026, and this is still a proposed rule. Nothing here is current law, and the comment period exists specifically because FDA expects industry to push back on scope, timing, and cost before anything is finalized.

Why This Matters Before It’s Final

SnackStack’s read: this matters more to ingredient suppliers than to the brands buying from them, at least at first. A lot of the interesting compounds behind functional foods, protein systems, and better-for-you reformulations reach market through self-affirmed GRAS conclusions that never touch FDA’s desk. If notification becomes mandatory, ingredient companies lose the option to stay quiet, and brands doing due diligence on a new supplier will have an actual FDA-facing paper trail to ask for instead of just a technical dossier and a handshake. That’s a real change in how fast novel ingredients can move and how much brands can verify before they commit to a formulation. It’s not FDA blocking new ingredients. It’s FDA finally asking to see the guest list.